- Trial phase
- Approved
- Time to market
- Already approved and marketed since February 2014.
- Why 4/10
- VIMIZIM is an already-approved, marketed drug with no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. It is one of several revenue drivers within BioMarin's diversified portfolio. Per the rubric, an approved drug with no imminent regulatory decision scores 3-5; a default of 4 applies.
VIMIZIM is a mature, approved revenue driver with no binary catalyst ahead. Watch for any biosimilar entry (projected exclusivity loss around 2026-2029) and for quarterly revenue trends in BioMarin's Metabolic Conditions segment, which includes VIMIZIM alongside newer acquired assets. The next major BioMarin catalyst is the VOXZOGO PDUFA for hypochondroplasia on May 30, 2027, not VIMIZIM.
Price Chart
Executive Summary
VIMIZIM (elosulfase alfa) is BioMarin Pharmaceutical's enzyme replacement therapy for Morquio A syndrome (MPS IVA), a rare genetic lysosomal storage disorder. FDA-approved in February 2014, it is the first and only approved treatment for this indication. VIMIZIM generated approximately $740 million in net product revenue in 2024, making it one of BioMarin's top three products. In Q3 2026, BioMarin's Metabolic Conditions segment (which includes VIMIZIM) grew 44% year-over-year, with higher VIMIZIM revenue cited as a contributor. The drug faces eventual biosimilar competition risk as exclusivity protections expire, but currently enjoys a monopoly position in a small, durable patient population requiring chronic weekly dosing. BioMarin (BMRN, Nasdaq) is a diversified rare-disease biotech with multiple approved products; VIMIZIM is a mature commercial asset with no near-term binary catalyst.
How It Works
VIMIZIM is an enzyme replacement therapy (ERT) for Morquio A syndrome, a rare genetic disorder where patients lack a working version of the enzyme GALNS. Without this enzyme, certain sugar molecules (GAGs) build up in cells and damage organs, bones, and connective tissue. VIMIZIM is a lab-made version of the missing enzyme, given as a weekly intravenous infusion, that helps break down the accumulated waste material.
Trial Status
VIMIZIM is fully approved and commercially marketed. Post-marketing studies (e.g., NCT02294877, an observational long-term safety and effectiveness study) are ongoing or completed. No new pivotal trials are underway for this indication.
The Two-Sided Case
Upcoming Catalysts
- No VIMIZIM-specific binary catalysts are scheduled. BioMarin's next major catalyst is the VOXZOGO PDUFA target action date for hypochondroplasia on May 30, 2027.
- Quarterly revenue trends in the Metabolic Conditions segment (which includes VIMIZIM) will be reported with BioMarin's Q4 2026 earnings, expected in February 2027.
- Any biosimilar development or patent challenge announcements would be a negative catalyst for VIMIZIM's long-term revenue outlook.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report